Explainer
Fatty liver disease (MASLD and MASH) and the first approved drugs
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly NAFLD, is a build-up of excess fat in the liver not caused by heavy drinking; about 24% of US adults have it.[1][2] In a minority it becomes MASH, with inflammation and scarring that can lead to cirrhosis and liver cancer.[2][3][4] Weight loss is the core treatment, and since 2024 the FDA has granted accelerated approval to the first MASH drugs, Rezdiffra (resmetirom) and Wegovy (semaglutide), for people with moderate to advanced scarring.[5][6][7][8]
The condition long called nonalcoholic fatty liver disease (NAFLD) is now also called metabolic dysfunction-associated steatotic liver disease (MASLD).[1] It is closely tied to obesity and type 2 diabetes.[9] Until 2024 there was no approved drug for its more serious form with liver scarring.[6] This page explains the condition, who gets it, how it is diagnosed and the treatments now available.
This page is general information, not medical advice. It does not give doses. Talk to a doctor about liver tests, weight loss and whether any medicine is right for you. Drug results here come from the FDA and from randomised trials measured by liver biopsy; long-term outcome results are still pending.
MASLD and MASH
MASLD is a build-up of excess fat in the liver that is not caused by heavy alcohol use.[1] It has two forms:
- Simple fatty liver (NAFL, or MASL): fat in the liver with little or no inflammation or damage.[3] It usually does not progress to liver damage.[4]
- Steatohepatitis (NASH, or MASH): fat plus liver inflammation and damage.[3] The inflammation can cause fibrosis, or scarring, which may progress to cirrhosis, permanent scarring of the liver.[4]
People with MASH have a higher chance of dying from liver-related causes, but cardiovascular disease is the most common cause of death in people with MASLD.[10] Losing weight may turn MASH back into simple fatty liver, and regaining it may do the reverse.[11]
Who gets it
NIDDK says experts estimate about 24% of US adults have MASLD and about 1.5% to 6.5% have MASH.[2] Studies suggest one-third to two-thirds of people with type 2 diabetes have MASLD. Research suggests it is present in up to 75% of people with overweight and more than 90% of people with severe obesity.[9] Close to 10% of US children aged 2 to 19 may have it.[12] The obesity explainer covers the related metabolic picture.
Symptoms and diagnosis
MASLD is usually silent, with few or no symptoms even at the cirrhosis stage. Some people feel tired or have discomfort in the upper right abdomen.[13]
A blood test showing raised liver enzymes can make a doctor suspect it. Doctors can then use simple scores, scans that measure how stiff the liver is, and sometimes a small tissue sample (biopsy) to see how much damage there is.[14][15]
Raised ALT and AST may prompt evaluation, and scores calculated from routine bloods, such as FIB-4 or APRI, help identify or rule out advanced fibrosis. Routine imaging shows fat but not inflammation or fibrosis. Elastography estimates liver stiffness as a marker of advanced fibrosis.[14][15] Biopsy remains the only test that can prove MASH and stage its severity.[14]
Treatment: weight loss first
Citing American Association for the Study of Liver Diseases guidance, NIDDK says losing at least 3% to 5% of body weight can reduce liver fat. Losing up to 7% to 10% may be needed to reduce inflammation and fibrosis. Physical activity helps even without weight loss, but rapid weight loss can make liver disease worse.[5] NIDDK advises talking to a doctor before using supplements, because some herbal remedies can damage the liver.[16]
The first MASH drugs
Rezdiffra (resmetirom). On 14 March 2024 the FDA approved Rezdiffra, the first treatment for adults with MASH (then called NASH) who have moderate to advanced liver scarring but not cirrhosis. It is used alongside diet and exercise.[6] It partially activates a thyroid hormone receptor in the liver, which reduces liver fat.[17] In the randomised, placebo-controlled trial of 888 people behind the approval, 24% to 36% of those on Rezdiffra had MASH resolve without worse scarring after 12 months, compared with 9% to 13% on placebo. The ranges cover two dose groups and readings by different pathologists.[18]
The approval was an accelerated one, based on biopsy findings at 12 months, and an ongoing 54-month study must confirm clinical benefit.[7] The most common side effects were diarrhoea and nausea. The drug should be avoided in decompensated cirrhosis and can interact with some medicines, notably statins.[19]
Wegovy (semaglutide). In the ESSENCE trial in people with MASH and moderate or advanced fibrosis, MASH resolved without worse scarring in 62.9% of people on semaglutide versus 34.3% on placebo at 72 weeks, in a planned interim analysis.[20] In August 2025 the FDA granted Wegovy accelerated approval for noncirrhotic MASH with moderate to advanced fibrosis.[8] See semaglutide and the GLP-1 explainer.
Read next: chronic kidney disease, another common silent condition linked to diabetes, and the metabolic medicine crash course.
Read next
Semaglutide
Semaglutide (Ozempic, Wegovy, Rybelsus, Wegovy pill) is Novo Nordisk's GLP-1 drug. Its trials, approvals, oral forms, prices and patent status in 2026.
Questions readers ask
What is the difference between NAFLD, MASLD and MASH?
NAFLD and MASLD are two names for the same condition, a build-up of excess fat in the liver not caused by heavy alcohol use. MASH (formerly NASH) is the more serious form, with liver inflammation and damage as well as fat.[1][3]
How common is fatty liver disease?
NIDDK says experts estimate about 24% of US adults have MASLD and about 1.5% to 6.5% have MASH. Studies suggest one-third to two-thirds of people with type 2 diabetes have it.[2][9]
What are the symptoms of fatty liver disease?
Usually none, even at the cirrhosis stage. Some people feel tired or have discomfort in the upper right part of the abdomen.[13]
How much weight loss helps fatty liver?
Citing guidance from the American Association for the Study of Liver Diseases, NIDDK says losing at least 3% to 5% of body weight can reduce liver fat, and up to 7% to 10% may be needed to reduce inflammation and scarring. Rapid weight loss can make liver disease worse.[5]
Is there a drug for fatty liver disease?
Yes, for some people. In March 2024 the FDA approved Rezdiffra (resmetirom) for adults with MASH and moderate to advanced liver scarring but no cirrhosis, alongside diet and exercise. In August 2025 it gave Wegovy accelerated approval for the same group. Both were accelerated approvals. Rezdiffra's rests on liver biopsy results at 12 months, and a longer study must confirm its clinical benefit.[6][7][8]
How is MASH diagnosed?
Blood tests, including liver enzymes and scores such as FIB-4, imaging and elastography can point to it. A liver biopsy is the only test that can prove MASH and show how severe it is.[14]
Sources
· 20 claims from 5 publishers
Each numbered claim is a statement we checked against the sources listed with it. Tap a number in the text to see its sources in place.
- [1]
Nonalcoholic fatty liver disease (NAFLD), also called metabolic dysfunction-associated steatotic liver disease (MASLD), is a build-up of excess fat in the liver that is not caused by heavy alcohol use. confirmedas of 2026-11-07
- Definition & Facts of Metabolic Dysfunction-associated Steatotic Liver Disease · National Institute of Diabetes and Digestive and Kidney Diseases (NIH) · Primary source · Definition (retrieved 2026-11-07)
- Definition & Facts of Metabolic Dysfunction-associated Steatotic Liver Disease · National Institute of Diabetes and Digestive and Kidney Diseases (NIH) · Primary source · Definition (retrieved 2026-11-07)
- [2]
Experts estimate about 24% of US adults have MASLD and about 1.5% to 6.5% have MASH, according to NIDDK. confirmedas of 2026-11-07
- Definition & Facts of Metabolic Dysfunction-associated Steatotic Liver Disease · National Institute of Diabetes and Digestive and Kidney Diseases (NIH) · Primary source · How common (retrieved 2026-11-07)
- [3]
MASLD has two types: simple fatty liver (NAFL, or MASL), with little or no inflammation or damage, and steatohepatitis (NASH, or MASH), with liver inflammation and damage as well as fat. confirmedas of 2026-11-07
- Definition & Facts of Metabolic Dysfunction-associated Steatotic Liver Disease · National Institute of Diabetes and Digestive and Kidney Diseases (NIH) · Primary source · Types (retrieved 2026-11-07)
- Definition & Facts of Metabolic Dysfunction-associated Steatotic Liver Disease · National Institute of Diabetes and Digestive and Kidney Diseases (NIH) · Primary source · Types (retrieved 2026-11-07)
- [4]
The inflammation of MASH can cause fibrosis (scarring), which may progress to cirrhosis, permanent scarring that can lead to liver cancer; simple fatty liver usually does not progress to liver damage. confirmedas of 2026-11-07
- Definition & Facts of Metabolic Dysfunction-associated Steatotic Liver Disease · National Institute of Diabetes and Digestive and Kidney Diseases (NIH) · Primary source · Types (retrieved 2026-11-07)
- Definition & Facts of Metabolic Dysfunction-associated Steatotic Liver Disease · National Institute of Diabetes and Digestive and Kidney Diseases (NIH) · Primary source · Types (retrieved 2026-11-07)
- Definition & Facts of Metabolic Dysfunction-associated Steatotic Liver Disease · National Institute of Diabetes and Digestive and Kidney Diseases (NIH) · Primary source · Types (retrieved 2026-11-07)
- [5]
Citing AASLD guidance, NIDDK says losing at least 3% to 5% of body weight can reduce liver fat, losing up to 7% to 10% may be needed to reduce inflammation and fibrosis, physical activity helps even without weight loss, and rapid weight loss can make liver disease worse. confirmedas of 2026-11-07
- Treatment of MASLD · National Institute of Diabetes and Digestive and Kidney Diseases (NIH) · Primary source · Weight loss (retrieved 2026-11-07)
- Treatment of MASLD · National Institute of Diabetes and Digestive and Kidney Diseases (NIH) · Primary source · Weight loss (retrieved 2026-11-07)
- Treatment of MASLD · National Institute of Diabetes and Digestive and Kidney Diseases (NIH) · Primary source · Weight loss (retrieved 2026-11-07)
- Treatment of MASLD · National Institute of Diabetes and Digestive and Kidney Diseases (NIH) · Primary source · Weight loss (retrieved 2026-11-07)
- Treatment of MASLD · National Institute of Diabetes and Digestive and Kidney Diseases (NIH) · Primary source · Reference 5, cited for the weight-loss figures (retrieved 2026-11-07)
- [6]
On 14 March 2024 the FDA approved Rezdiffra (resmetirom), the first treatment for adults with noncirrhotic MASH (then called NASH) with moderate to advanced liver scarring, to be used with diet and exercise. confirmedas of 2024-03-14
- FDA Approves First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease · U.S. Food and Drug Administration · Primary source · 2024-03-14 · Press announcement, 14 March 2024 (retrieved 2026-11-07)
- [7]
Rezdiffra received accelerated approval based on a surrogate endpoint from liver biopsies at 12 months; an ongoing 54-month study must confirm clinical benefit. confirmedas of 2024-03-14
- FDA Approves First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease · U.S. Food and Drug Administration · Primary source · 2024-03-14 · Press announcement (retrieved 2026-11-07)
- FDA Approves First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease · U.S. Food and Drug Administration · Primary source · 2024-03-14 · Press announcement (retrieved 2026-11-07)
- FDA Approves First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease · U.S. Food and Drug Administration · Primary source · 2024-03-14 · Press announcement (retrieved 2026-11-07)
- [8]
In August 2025 the FDA granted Wegovy accelerated approval for noncirrhotic MASH with moderate to advanced (F2 to F3) liver fibrosis. confirmedas of 2025-08-15
- Novo Nordisk Form 6-K, 15 August 2025 (Wegovy accelerated approval for MASH) · Novo Nordisk (SEC filing) · Primary source · 2025-08-15 (retrieved 2026-10-10)
- WEGOVY (semaglutide): FDA-approved prescribing information (DailyMed, SPL version 19, June 2026) · U.S. National Library of Medicine (DailyMed) · Primary source · 2026-06-30 · Highlights, Indications and Usage (1) (retrieved 2026-11-14)
- WEGOVY (semaglutide): FDA-approved prescribing information (DailyMed, SPL version 19, June 2026) · U.S. National Library of Medicine (DailyMed) · Primary source · 2026-06-30 · Highlights, Indications and Usage (1) (retrieved 2026-11-14)
- [9]
Studies suggest one-third to two-thirds of people with type 2 diabetes have MASLD, and research suggests it is present in up to 75% of people with overweight and more than 90% of people with severe obesity. confirmedas of 2026-11-07
- Definition & Facts of Metabolic Dysfunction-associated Steatotic Liver Disease · National Institute of Diabetes and Digestive and Kidney Diseases (NIH) · Primary source · Who is more likely (retrieved 2026-11-07)
- Definition & Facts of Metabolic Dysfunction-associated Steatotic Liver Disease · National Institute of Diabetes and Digestive and Kidney Diseases (NIH) · Primary source · Who is more likely (retrieved 2026-11-07)
- [10]
Cardiovascular disease is the most common cause of death in people with MASLD, and people with MASH have a higher chance of dying from liver-related causes. confirmedas of 2026-11-07
- Definition & Facts of Metabolic Dysfunction-associated Steatotic Liver Disease · National Institute of Diabetes and Digestive and Kidney Diseases (NIH) · Primary source · Complications (retrieved 2026-11-07)
- Definition & Facts of Metabolic Dysfunction-associated Steatotic Liver Disease · National Institute of Diabetes and Digestive and Kidney Diseases (NIH) · Primary source · Complications (retrieved 2026-11-07)
- [11]
Losing weight may turn MASH back into simple fatty liver, and regaining weight may cause the reverse. confirmedas of 2026-11-07
- Symptoms & Causes of MASLD · National Institute of Diabetes and Digestive and Kidney Diseases (NIH) · Primary source · Causes (retrieved 2026-11-07)
- Symptoms & Causes of MASLD · National Institute of Diabetes and Digestive and Kidney Diseases (NIH) · Primary source · Causes (retrieved 2026-11-07)
- [12]
Research suggests close to 10% of US children aged 2 to 19 have MASLD. confirmedas of 2026-11-07
- Definition & Facts of Metabolic Dysfunction-associated Steatotic Liver Disease · National Institute of Diabetes and Digestive and Kidney Diseases (NIH) · Primary source · Who is more likely (retrieved 2026-11-07)
- [13]
MASLD is usually silent, with few or no symptoms even at the cirrhosis stage; some people feel tired or have discomfort in the upper right abdomen. confirmedas of 2026-11-07
- Symptoms & Causes of MASLD · National Institute of Diabetes and Digestive and Kidney Diseases (NIH) · Primary source · Symptoms (retrieved 2026-11-07)
- Symptoms & Causes of MASLD · National Institute of Diabetes and Digestive and Kidney Diseases (NIH) · Primary source · Symptoms (retrieved 2026-11-07)
- [14]
MASLD is diagnosed with blood tests (raised ALT and AST liver enzymes and scores such as FIB-4), imaging, elastography to measure liver stiffness, and sometimes biopsy, the only test that can prove MASH and show its severity. confirmedas of 2026-11-07
- Diagnosis of MASLD · National Institute of Diabetes and Digestive and Kidney Diseases (NIH) · Primary source · Blood tests (retrieved 2026-11-07)
- Diagnosis of MASLD · National Institute of Diabetes and Digestive and Kidney Diseases (NIH) · Primary source · Blood tests (retrieved 2026-11-07)
- Diagnosis of MASLD · National Institute of Diabetes and Digestive and Kidney Diseases (NIH) · Primary source · Liver biopsy (retrieved 2026-11-07)
- [15]
Routine imaging can show fat in the liver but not inflammation or fibrosis; elastography can help detect advanced fibrosis by measuring liver stiffness. confirmedas of 2026-11-07
- Diagnosis of MASLD · National Institute of Diabetes and Digestive and Kidney Diseases (NIH) · Primary source · Imaging tests (retrieved 2026-11-07)
- Diagnosis of MASLD · National Institute of Diabetes and Digestive and Kidney Diseases (NIH) · Primary source · Imaging tests (retrieved 2026-11-07)
- [16]
NIDDK advises talking with a doctor before using supplements or herbal remedies, some of which can damage the liver. confirmedas of 2026-11-07
- Treatment of MASLD · National Institute of Diabetes and Digestive and Kidney Diseases (NIH) · Primary source · Supplements (retrieved 2026-11-07)
- Treatment of MASLD · National Institute of Diabetes and Digestive and Kidney Diseases (NIH) · Primary source · Supplements (retrieved 2026-11-07)
- [17]
Rezdiffra partially activates a thyroid hormone receptor in the liver, which reduces liver fat accumulation. confirmedas of 2024-03-14
- FDA Approves First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease · U.S. Food and Drug Administration · Primary source · 2024-03-14 · Press announcement (retrieved 2026-11-07)
- [18]
In the randomised, placebo-controlled trial of 888 people behind the approval, 24% to 36% of those on Rezdiffra (across two dose groups and pathologists' readings) had MASH resolve without worse scarring at 12 months, against 9% to 13% on placebo. confirmedas of 2024-03-14
- FDA Approves First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease · U.S. Food and Drug Administration · Primary source · 2024-03-14 · Press announcement (retrieved 2026-11-07)
- FDA Approves First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease · U.S. Food and Drug Administration · Primary source · 2024-03-14 · Press announcement (retrieved 2026-11-07)
- FDA Approves First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease · U.S. Food and Drug Administration · Primary source · 2024-03-14 · Press announcement (retrieved 2026-11-07)
- [19]
Rezdiffra's most common side effects were diarrhoea and nausea; it should be avoided in decompensated cirrhosis and can interact with some drugs, notably statins. confirmedas of 2024-03-14
- FDA Approves First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease · U.S. Food and Drug Administration · Primary source · 2024-03-14 · Press announcement (retrieved 2026-11-07)
- FDA Approves First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease · U.S. Food and Drug Administration · Primary source · 2024-03-14 · Press announcement (retrieved 2026-11-07)
- FDA Approves First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease · U.S. Food and Drug Administration · Primary source · 2024-03-14 · Press announcement (retrieved 2026-11-07)
- [20]
In part 1 of the ESSENCE trial in people with MASH and moderate or advanced liver fibrosis, steatohepatitis resolved without worsening fibrosis in 62.9% on semaglutide versus 34.3% on placebo at 72 weeks, in a planned interim analysis of the ongoing 240-week trial based on liver histology. confirmedas of 2025-04-30
- Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis (ESSENCE) · The New England Journal of Medicine · Primary source · 2025-04-30 · Abstract (retrieved 2026-10-10)
- Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis (ESSENCE) · The New England Journal of Medicine · Primary source · 2025-04-30 · Abstract (retrieved 2026-10-10)
Revision history (1)
- Page created.
Created Nov 7, 2026. Last reviewed by an editor on Nov 8, 2026. Next scheduled review: Feb 7, 2027.
Cite this page
"Fatty liver disease (MASLD and MASH) and the first approved drugs." ContentLora, updated Nov 7, 2026. https://contentlora.com/explain/fatty-liver-disease-explained
Spotted an error? Suggest a correction or emailcorrections@contentlora.com.